Analysts Set Intellia Therapeutics Inc (NASDAQ:NTLA) Target Price at $26.92

Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) have received a consensus rating of “Hold” from the thirteen brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $26.92.

NTLA has been the topic of a number of recent analyst reports. BidaskClub raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 27th. Chardan Capital reissued a “buy” rating and issued a $57.50 price objective on shares of Intellia Therapeutics in a research report on Wednesday, February 27th. Evercore ISI initiated coverage on shares of Intellia Therapeutics in a research report on Thursday, April 11th. They issued an “outperform” rating on the stock. Wedbush raised shares of Intellia Therapeutics from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $20.00 to $21.00 in a research report on Friday, May 3rd. Finally, Zacks Investment Research downgraded shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 7th.

Several institutional investors have recently modified their holdings of the company. Elmwood Wealth Management Inc. boosted its stake in shares of Intellia Therapeutics by 122.1% during the 1st quarter. Elmwood Wealth Management Inc. now owns 136,849 shares of the company’s stock worth $2,337,000 after purchasing an additional 75,227 shares during the last quarter. ARK Investment Management LLC boosted its position in shares of Intellia Therapeutics by 17.3% in the first quarter. ARK Investment Management LLC now owns 7,981,198 shares of the company’s stock worth $136,319,000 after acquiring an additional 1,179,246 shares during the last quarter. Resources Investment Advisors Inc. acquired a new stake in shares of Intellia Therapeutics in the first quarter worth approximately $92,000. NumerixS Investment Technologies Inc acquired a new stake in shares of Intellia Therapeutics in the first quarter worth approximately $110,000. Finally, DekaBank Deutsche Girozentrale boosted its position in shares of Intellia Therapeutics by 22.7% in the first quarter. DekaBank Deutsche Girozentrale now owns 20,000 shares of the company’s stock worth $624,000 after acquiring an additional 3,700 shares during the last quarter. Institutional investors and hedge funds own 74.34% of the company’s stock.



Shares of Intellia Therapeutics stock traded down $0.11 on Friday, reaching $14.78. The company had a trading volume of 18,788 shares, compared to its average volume of 429,776. The business has a 50 day simple moving average of $14.92. The stock has a market cap of $692.05 million, a price-to-earnings ratio of -7.45 and a beta of 2.58. Intellia Therapeutics has a 52-week low of $11.03 and a 52-week high of $32.95. The company has a current ratio of 7.74, a quick ratio of 7.74 and a debt-to-equity ratio of 0.06.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, May 2nd. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04. Intellia Therapeutics had a negative net margin of 257.28% and a negative return on equity of 31.68%. The firm had revenue of $10.43 million for the quarter, compared to the consensus estimate of $9.43 million. During the same period in the prior year, the firm earned ($0.51) EPS. The firm’s revenue for the quarter was up 39.7% on a year-over-year basis. Analysts anticipate that Intellia Therapeutics will post -2.43 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

Further Reading: Accumulation/Distribution

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.